| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 40/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Paclitaxel |
| CAS NO. | 33069-62-4 |
| Specification | 99% |
| Appearance | White powder |
| packing | 1kg/bag,25kgs/drum |
| MOQ | 1KG |
Paclitaxel, PTX, is a highly effective, low-toxic, broad-spectrum natural anticancer drug with a molecular formula of C47H51NO14. It has been widely used in the clinical treatment of breast cancer, ovarian cancer, and some head and neck cancers and lung cancers. As a diterpene alkaloid compound with anticancer activity, paclitaxel has attracted much attention from botanists, chemists and scientists due to its novel and complex chemical structure, extensive and significant biological activity, new and unique mechanism of action, and scarce natural resources. It was greatly favored by scientists, pharmacologists, and molecular biologists, making it a world-renowned anti-cancer star and research focus in the second half of the 20th century. Paclitaxel is known as a chemotherapeutic drug that can inhibit the proliferation of cancer cells by inducing cell cycle arrest and inducing mitotic catastrophe. It is well known that paclitaxel can induce multiple cell death in cancer. In addition to inducing mitotic catastrophe during mitosis, paclitaxel has been shown to induce the expression of several pro-apoptotic mediators, and it can also modulate the activity of anti-apoptotic mediators.
Paclitaxel is a natural secondary metabolite isolated and purified from the bark of the gymnosperm Taxus chinensis. It has been clinically proven to have good anti-tumor effects [15], especially for ovarian cancer, uterine cancer and breast cancer, which have a high incidence rate. Paclitaxel is the most popular anti-cancer drug in the international market in recent years and is considered to be one of the most effective anti-cancer drugs for humans in the next 20 years.
In recent years, the global population and cancer incidence have exploded, and the demand for paclitaxel has also increased significantly. Paclitaxel required for clinical and scientific research is mainly extracted directly from Taxus chinensis. Since the content of paclitaxel in the plant is quite low (the bark of Taxus brevis, which is recognized to have the highest content, is only 0.069%), about 13.6 kg of bark can extract 1 g of paclitaxel. To treat an ovarian cancer patient, 3-12 Taxus chinensis trees over 100 years old are needed. As a result, a large number of Taxus chinensis trees have been cut down, causing this precious tree species to be on the verge of extinction. In addition, the resources of yew itself are very scarce, and the growth of yew plants is slow, which has caused great difficulties for the further development and utilization of paclitaxel.
The biosynthetic pathway of paclitaxel has been basically elucidated. From the common diterpenoid precursor geranyl diphosphate to paclitaxel itself, there are about 20 enzymatic steps. This complex process can be divided into three parts: the source and formation of the taxane core, the modification of the taxane core skeleton, the synthesis of the ß-phenylpropanyl coenzyme A side chain, and the assembly of paclitaxel. Although chemical synthesis has been completed, it has no industrial significance due to the strict conditions required, low yield, and high cost. Now the semi-synthetic method of paclitaxel is relatively mature and is considered to be an effective way to expand the source of paclitaxel in addition to artificial cultivation. The semi-synthetic method can make greater use of plant resources, but it is no different from the method of directly extracting paclitaxel. It requires the consumption of a large number of yew trees and still cannot fundamentally solve the problem of lack of plant sources. Obviously, the extraction of paclitaxel from yew plant tissues is greatly limited, and it is of great significance to find new ways to obtain paclitaxel.
| Item | Specification | Test result |
| Appearance | white powder | Conforms |
| Assay | 99% | Conforms |
| Heavy metal | ≤10ppm | Conforms |
| Lead | ≤2.0ppm | Conforms |
| As | ≤2.0ppm | Conforms |
| Ca | ≤1.0ppm | Conforms |
| Me | ≤0.1ppm | Conforms |
| Total aerobic microbial count | ≤1000CFU/g | Conforms |
| Total moulds&yeast count | ≤100CFU/g | Conforms |
| Enterobacterial | ≤10MPN/g | Conforms |
| Salmonella | N.D/25g | Conforms |
| Escherichia coli | N.D/10g | Conforms |
| Staphylococcus aureus | N.D/10g | Conforms |
| Pseudomonas aeruginosa | N.D/10g | Conforms |
| Conclusion: Conform with specification. | ||
Paclitaxel is an anti-tumor drug commonly used to treat metastatic breast cancer and its recurrence. Previous chemotherapy should include an anthracycline anti-cancer drug.
Indications
It is used to treat advanced ovarian cancer, advanced or metastatic non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
){kind=link}